SOLEYSCREEN
LIVE

Serial Number

97842862

Owner

Soley Therapeutics, Inc.

Attorney

John L. Slafsky

Filing Date

Mar 16, 2023

Add to watchlist:

No watchlists yet
View on USPTO

SOLEYSCREEN Trademark

Serial Number: 97842862

SOLEYSCREEN is a trademark filed by Soley Therapeutics, Inc. on March 16, 2023. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Soley Therapeutics, Inc. (6 trademarks)

1 Corporate Drive
South San Francisco, CA 94080

Entity Type: 03

Trademark Details

Filing Date

March 16, 2023

Registration Date

Not Registered

Published for Opposition

February 6, 2024

Goods & Services

downloadable computer software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis; downloadable computer software, namely, software for use in generating, analyzing, and accessing data via advanced computational techniques, automation, infrastructure, artificial intelligence, and machine learning; downloadable computer software for discovering drugs, forecasting potential uses of drug compounds and generating insights from screening and analyzing molecules, all using advanced computational techniques, automation, infrastructure, artificial intelligence, machine learning, insilico, virtual screening, and generative chemistry; downloadable computer software for analyzing molecular data in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis for biotechnology and pharmaceutical companies

drug discovery services; pharmaceutical research and development services; providing online non-downloadable computer software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis; software as a service (SAAS) services featuring software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis; providing online non-downloadable computer software for use in generating, analyzing, and accessing data via advanced computational techniques, automation, infrastructure, artificial intelligence, and machine learning; software as a service (SAAS) services featuring software for use in generating, analyzing, and accessing data via advanced computational techniques, automation, infrastructure, artificial intelligence, and machine learning; providing an online non-downloadable computer software platform for discovering drugs, forecasting potential uses of drug compounds and generating insights from screening and analyzing molecules, featuring software using advanced computational techniques, automation, infrastructure, artificial intelligence, machine learning, insilico, virtual screening, and generative chemistry; software as a service (SAAS) services featuring software for discovering drugs, forecasting potential uses of drug compounds and generating insights from screening and analyzing molecules, all using advanced computational techniques, automation, infrastructure, artificial intelligence, machine learning, insilico, virtual screening, and generative chemistry; providing an online non-downloadable computer software platform for analyzing molecular data in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis for biotechnology and pharmaceutical companies; software as a service (SAAS) services featuring software for analyzing molecular data in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis for biotechnology and pharmaceutical companies; preclinical drug discovery and development services used for identifying, designing, and optimizing chemical compounds; pharmaceutical evaluation and preclinical evaluation of chemical series and chemical compounds in drug discovery; pharmaceutical drug development and discovery services, namely, identifying, designing, optimizing, and developing chemical series and chemical compounds via software using advanced computational techniques, automation, infrastructure, artificial intelligence, machine learning, computational modeling, high-throughput screening, medicinal chemistry, biology, pharmacology, insilico, virtual screening, and generative chemistry; providing an online searchable database in the fields of pharmaceuticals for scientific research purposes, in particular, pharmaceutical research and development, scientific research and development of pharmaceutical preparations, scientific development of new uses for pharmaceutical compounds, and scientific technical research; scientific research and development for forecasting the use of molecules as drug compounds and developing new uses for pharmaceutical compounds; research and development in the field of drug discovery and development, molecular screening, phenomics, genetics, genomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis; drug discovery services, namely, phenotypic screening services for discovering novel molecules to develop into drug compounds

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 6, 2026 EXRA
SOU EXTENSION 4 GRANTED
Jan 5, 2026 EX4G
SOU EXTENSION 4 FILED
Jan 5, 2026 EXT4
SOU TEAS EXTENSION RECEIVED
Jan 5, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 23, 2025 EXRA
SOU EXTENSION 3 GRANTED
Jul 22, 2025 EX3G
SOU EXTENSION 3 FILED
Jul 22, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Jul 22, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 4, 2025 EXRA
SOU EXTENSION 2 GRANTED
Jan 24, 2025 EX2G
SOU EXTENSION 2 FILED
Jan 23, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Jan 23, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 19, 2024 EXRA
SOU EXTENSION 1 GRANTED
Aug 19, 2024 EX1G
SOU EXTENSION 1 FILED
Aug 19, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 19, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 2, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 6, 2024 NPUB
PUBLISHED FOR OPPOSITION
Feb 6, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 17, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 28, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 20, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 20, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 20, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 14, 2023 GNRN
NON-FINAL ACTION E-MAILED
Dec 14, 2023 GNRT
NON-FINAL ACTION WRITTEN
Dec 14, 2023 CNRT
ASSIGNED TO EXAMINER
Dec 13, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 7, 2023 NWOS
NEW APPLICATION ENTERED
Mar 20, 2023 NWAP